Compare PED & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | IVVD |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 692.7M |
| IPO Year | N/A | 2021 |
| Metric | PED | IVVD |
|---|---|---|
| Price | $0.54 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.50 | ★ $8.33 |
| AVG Volume (30 Days) | 169.0K | ★ 12.4M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $33,244,999.00 | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | $305.89 | $171.40 |
| P/E Ratio | $5.14 | ★ N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $0.43 | $0.35 |
| 52 Week High | $1.00 | $3.07 |
| Indicator | PED | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 54.13 |
| Support Level | $0.55 | $2.15 |
| Resistance Level | $0.61 | $2.59 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 61.10 | 50.50 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.